In this phase I multicenter, international, open-label, randomized expansion of the KEYNOTE-001 cohort, 173 patients with advanced or unresectable melanoma who had previously failed treatment with ipilimumab and a BRAF inhibitor (if BRAFV600-mutated) were treated with pembrolizumab [14]. Here, BRAF is linked to melanoma.